PYC Therapeutics Limited (ASX:PYC)

Market Cap	1.29B +121.6%
Revenue (ttm)	20.56M -17.7%
Net Income	-47.56M
EPS	-0.09
Shares Out	983.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	528,928
Average Volume	1,160,896
Open	1.320
Previous Close	1.310
Day's Range	1.290 - 1.320
52-Week Range	0.847 - 1.755
Beta	1.01
RSI	56.13
Earnings Date	May 22, 2026

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 5
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PYC

Financial Performance

In fiscal year 2025, PYC Therapeutics's revenue was 23.49 million, an increase of 6.51% compared to the previous year's 22.06 million. Losses were -50.30 million, 33.3% more than in 2024.